Heyholder
‹ Activism Filings

KYUNG NAM PHARM.CO.,LTD. Q3 revenue KRW 20.7 billion, operating loss KRW 1.3 billion

KYUNG NAM PHARM.CO.,LTD.· Periodic Report

AI summary · Not investment advice

Kyungnam Pharm sold KRW 20.7 billion in Q3 and lost KRW 1.3 billion from its main business; sales rose 46.2% from a year earlier and 16.3% from the prior quarter.

Operating profit · 3 months

KRW -1.3 billion

Key facts

Revenue (3 months)
KRW 20.7 billion
Net income (3 months)
KRW -2.9 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 14.2 billion
Revenue (year to date)
KRW 54.6 billion
Operating profit (prior-year 3 months)
KRW -1.1 billion
Operating profit (year to date)
KRW -1.1 billion
Net income (prior-year 3 months)
KRW -4.7 billion
Net income (year to date)
KRW -7.2 billion

Commentary

AI commentary · Not investment advice

What happened

Kyungnam Pharm reported its consolidated results for the third quarter of 2026. Sales for the quarter were KRW 20.71 billion. That is 46.2% more than the same 3 months a year earlier (KRW 14.16 billion) and 16.3% more than the previous quarter.

In the company's terms

Operating profit (profit from the core business) was a loss of KRW 1.31 billion for the quarter. A year earlier, the same 3 months showed a loss of KRW 1.06 billion. Net income was a loss of KRW 2.89 billion, compared with a loss of KRW 4.68 billion a year earlier.

What changes for shareholders

For the year to date (Jan 1 to Sep 30, 2026), sales were KRW 54.65 billion. Operating profit was a loss of KRW 1.14 billion. Net income was a loss of KRW 7.15 billion.

Comments

No comments yet

Comments from shareholders will appear here.